66191-92-2

Upstream product

• 685534-52-5 methyl (2E)-3-(2-bromo-4-chlorophenyl)acryIate 
• 84459-33-6 2-bromo-4-chlorobenzaldehyde 
• 67-56-1 methanol 
• 66192-17-4 2-(2-Bromo-4-chloro-benzyl)-malonic acid diethyl ester 

Downstream Products

• 66191-79-5 3-(4-Chloro-2-cyano-phenyl)-propionic acid methyl ester 
• 1260017-94-4 4-bromo-6-chloro-2,3-dihydro-1H-inden-1-one 
• 66192-04-9 3-(2-bromo-4-chlorophenyl)propanoic acid 

Relevant academic research and scientific papers

HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME

Disclosed are chemical entities which are compounds of formula (I); or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra', Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS

The present invention relates to compounds of general formula (I), wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.